Nuvalent, Inc. (NUVL) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 James R. Porter.
NUVL 을(를) 보유 IPO 날짜 2021-07-29, 162 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $7.69B.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's lead programs include NVL-520, a brain-penetrant ROS1-selective inhibitor currently in Phase I development designed to overcome drug resistance mutations, and NVL-655, a brain-penetrant ALK-selective inhibitor in Phase I/II clinical trials addressing treatment resistance and brain metastases. Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent is advancing precision oncology solutions for patients with ROS1 and ALK-driven cancers.
